Analysis of the disease burden of benign prostatic hyperplasia in China from 1990 to 2019

Objective　To analyze the disease burden of benign prostatic hyperplasia (BPH) in China from 1990 to 2019. Methods　Data were obtained from the Global Burden of Disease Study 2019. The prevalence, incidence, years lived with disability (YLD) and their corresponding age-standardized rate were used to compare the burden of BPH between China and the world from 1990 to 2019. In addition, a comparative analysis of YLD among 6 urinary diseases was also performed. Results　In 2019, the prevalent cases and incidence cases of BPH in China was approximately 20.34 million and 2.84 million, respectively, and the standardized prevalence rate and standardized incidence rate were 2220.85/100 000 and 280.64/100 000, respectively. In addition, the number of YLD due to BPH was approximately 0.41 million and the standardized YLD rate was 44.04/100 000. Compared with 1990, the prevalent cases, incident cases and YLD increased by 125.06%, 122.38% and 123.93% respectively, while the standardized prevalent rate, standardized incident rate and standardized YLD rate decreased by 14.69%, 10.09% and 14.83%, respectively. In 1990 and 2019, the prevalence rate and YLD rate of BPH in China were the highest in the age group ≥80 years old and increased with age. The incidence rate increased in the age group under 79 years old, but decreased in the age group ≥80 years old. In 2019, the YLD of BPH accounted for 61.15% of the 6 urinary diseases, which was 4.11 times that of prostate cancer. Conclusion　The disease burden of BPH in China remains at a high level in 2019. Health concerns and guidance on prevention and control should be strengthened for middle-aged and elderly men. DOI: 10.11855/j.issn.0577-7402.2021.10.05